|
|
| Viral Vector Based Gene Therapy Drug Products: The Right Primary Container | Packaging plays a critical role in ensuring the stability, safety, and efficacy of viral vector-based gene therapies. Key considerations include container closure integrity, low chemical reactivity, minimal extractables and leachables, reduced surface adsorption, and particulate control, particularly during ultra-low-temperature storage. Cyclic Olefin Polymer (COP) CZ vials address these challenges through high inertness, robust integrity, and compatibility with modern fill-finish processes, making them a reliable containment solution for advanced gene therapy products. |
|
|
|
|
By Irwin Hirsh, Q-Specialists AB | Amid gaining immediate access to external manufacturing capabilities, sponsor companies can lose the foundational understanding required to govern that capability. | |
|
|
| Removing Cost Barriers To Scalable AAV Manufacturing | Poster | By Vaughan R. Leydon, Siobhan Clerkin, Yi-Hsin Fan, et al., Minaris | Alternative AAV manufacturing approaches can dramatically reduce cost per dose, improve scalability, and increase yields across serotypes, enabling broader patient access to gene therapies. |
|
|
|
|
|
| Accelerating Antibody Discovery Through Linear Expression Technology | White Paper | By Derek Chen, Yu Liang, Lindi Wang, Wenwan Fang, and Jie Ma, ProBio | Integrating linear expression technology into single B cell workflows accelerates antibody discovery, enabling early functional screening, improved sensitivity, and cost-effective identification of diverse therapeutic candidates. |
|
|
|
| End-To-End Process Scalability For High Titer AAV Production | White Paper | By Phi Le, David Chiu, Migueal Betancourt, Jean-Phillipe Ayandokon, et al., Lonza | Explore how controlled bioreactor environments enable optimization of critical process parameters and support robust, scalable AAV production from development through manufacturing. |
|
|
|
|
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|
